Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes.

Jeannin, Anne-Caroline; Salem, Joe-Elie; Massy, Ziad; Aubert, Carole Elodie; Vemeer, Cees; Amouyal, Chloé; Phan, Franck; Halbron, Marine; Funck-Brentano, Christian; Hartemann, Agnès; Bourron, Olivier (2020). Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes. PLoS ONE, 15(2), e0229145. Public Library of Science 10.1371/journal.pone.0229145

[img]
Preview
Text
Jeannin PLoSOne 2020.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (544kB) | Preview
[img]
Preview
Text (Corrigendum 5th author name)
Jeannin PLoSOne 2020_corr.pdf - Additional Metadata
Available under License Creative Commons: Attribution (CC-BY).

Download (169kB) | Preview

AIMS/HYPOTHESIS Diabetic peripheral neuropathy is a frequent and severe complication of diabetes. As Matrix-gla-protein (MGP) is expressed in several components of the nervous system and is involved in some neurological disease, MGP could play a role in peripheral nervous system homeostasis. The aim of this study was to evaluate factors associated with sensitive diabetic neuropathy in Type 2 Diabetes, and, in particular, dephospho-uncarboxylated MGP (dp-ucMGP), the inactive form of MGP. METHODS 198 patients with Type 2 Diabetes were included. Presence of sensitive diabetic neuropathy was defined by a neuropathy disability score (NDS) ≥6. Plasma levels of dp-ucMGP were measured by ELISA. RESULTS In this cohort, the mean age was 64+/-8.4 years old, and 80% of patients were men. Peripheral neuropathy was present in 15.7% of the patients and was significantly associated (r = 0.51, p<0.0001) with dp-ucMGP levels (β = -0.26, p = 0.045) after integrating effects of height (β = -0.38, p = 0.01), insulin treatment (β = 0.42, p = 0.002), retinopathy treated by laser (β = 0.26, p = 0.02), and total cholesterol levels (β = 0.3, p = 0.03) by multivariable analysis. CONCLUSIONS The association between diabetic neuropathy and the inactive form of MGP suggests the existence of new pathophysiological pathways to explore. Further studies are needed to determine if dp-ucMGP may be used as a biomarker of sensitive neuropathy. Since dp-ucMGP is a marker of poor vitamin K status, clinical studies are warranted to explore the potential protective effect of high vitamin K intake on diabetic peripheral neuropathy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine
04 Faculty of Medicine > Medical Education > Institute of General Practice and Primary Care (BIHAM)

UniBE Contributor:

Aubert, Carole Elodie

Subjects:

300 Social sciences, sociology & anthropology > 360 Social problems & social services
600 Technology > 610 Medicine & health

ISSN:

1932-6203

Publisher:

Public Library of Science

Language:

English

Submitter:

Doris Kopp Heim

Date Deposited:

25 Feb 2020 16:10

Last Modified:

18 Jun 2020 06:14

Publisher DOI:

10.1371/journal.pone.0229145

PubMed ID:

32092076

BORIS DOI:

10.7892/boris.140961

URI:

https://boris.unibe.ch/id/eprint/140961

Actions (login required)

Edit item Edit item
Provide Feedback